Congress may have the votes to pass federal cannabis reform. That's the claim, anyway - courtesy of House Minority Leader Hakeem Jeffries, as reported by Marijuana Moment. Meanwhile, USDA data reveals American farmers produced $739 million worth of legal hemp last year, a number that looks thin against an industry estimated at roughly $30 billion. The latest episode of the Trade To Black podcast, presented by Flowhub and hosted by Shadd Dales and Anthony Varrell, pulls these threads together with market analysis, state-level policy fights, and a growing sense that something might actually be shifting - though "might" is doing heavy lifting in that sentence.
The Votes Are There. Maybe.
Jeffries's assertion that the House has sufficient support for federal cannabis reform is, on its face, encouraging. But anyone who's followed this issue for more than a cycle knows the pattern: promising rhetoric, bipartisan enthusiasm, then quiet legislative death by committee inaction or Senate indifference. The conversation is real. The follow-through, historically, has not been.
What makes this moment at least somewhat different is the convergence of pressure points. Reports suggest President Trump is pushing his Cabinet to finalize the cannabis rescheduling process - a move that would shift marijuana from Schedule I to Schedule III under the Controlled Substances Act. That wouldn't amount to legalization, but it would materially change the tax burden on cannabis operators and open doors for more research. Rescheduling has been stuck in bureaucratic review for what feels like an eternity. If the executive branch actually forces the issue, the downstream effects for state-legal businesses could be significant.
Still. We've been here before.
The Hemp Market's $739 Million Question
The USDA figure - $739 million in legal hemp production - sounds substantial until you hold it against the broader market. An industry valued near $30 billion doesn't get there on domestic, fully regulated hemp alone. The gap points to a problem the industry has struggled to address: unregulated products and chemical conversion processes that transform legal hemp-derived CBD into intoxicating cannabinoids like delta-8 THC. These products exist in a regulatory gray zone, sold widely but governed inconsistently across states. The scrutiny is increasing, and for good reason - consumers often have little visibility into what they're actually buying.
Dales and Varrell also touched on Kazmira's launch of a medical cannabis education platform, which signals where at least part of the industry wants to go: toward clinical legitimacy and healthcare integration. Whether the market rewards that approach over the wild-west retail model remains an open question.
Virginia's High-Stakes Standoff
In Virginia, legislators behind the state's recreational cannabis sales bill were prepared to reject Governor Abigail Spanberger's proposed amendments - even at the risk of a veto. That's a notable posture. It suggests lawmakers view the bill's current form as non-negotiable, or at least believe the political cost of concessions outweighs the risk of losing the legislation entirely. For Virginia consumers and prospective operators, the standoff introduces real uncertainty about when - or whether - regulated adult-use sales actually begin.
Markets React, Cautiously
Chart analyst Dan from The Chart Guys joined the podcast to dissect post-4/20 cannabis stock performance and the psychedelics sector, which surged after Trump's executive order fast-tracking psychedelic research. The analysis covered a broad slate: the AdvisorShares Pure US Cannabis ETF (MSOS), Trulieve, Curaleaf, Green Thumb Industries, High Tide, Tilray, and Organigram. The takeaway, in broad strokes, is that cannabis equities remain highly sensitive to policy signals - a dynamic that rewards headline-watchers but punishes anyone looking for fundamentals-driven stability.
The psychedelics surge is worth noting separately. An executive order accelerating research doesn't guarantee commercial viability, but it does create a framework that didn't exist before. Capital tends to follow frameworks.
Alignment Without Certainty
Here's the thing: multiple threads - rescheduling pressure, bipartisan congressional rhetoric, state-level legalization fights, executive action on psychedelics - are converging in a way that feels directionally meaningful. But convergence isn't the same as resolution. The cannabis industry has spent years watching promising signals dissolve into inertia. Whether this time proves different depends less on the votes that may exist and more on the political will to actually call them. The full discussion is available on the latest Trade To Black episode.
